Differential role of cholecystokinin receptor subtypes in opioid modulation of ongoing maternal behavior

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 1, 1999, Pages 165-169

  Miranda Paiva, Cláudia M ^a   Felicio, Luciano F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CCK(A); CCK(B); CCK 8; CCK1; CCK2; L 365,260; Lorglumide; Morphine; Opioids; Parental care

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; LORGLUMIDE; MORPHINE; RECEPTOR SUBTYPE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MATERNAL BEHAVIOR; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BENZODIAZEPINONES; FEMALE; HORMONE ANTAGONISTS; LACTATION; MATERNAL BEHAVIOR; MORPHINE; NARCOTICS; PHENYLUREA COMPOUNDS; PROGLUMIDE; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0032868432     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00117-3     Document Type: Article

References (54)

1. Alexander, S. P. H.; Peters, J. A.: 1998 Receptor & ion channel nomenclature supplement. Trends Pharmacol. Sci. Supp. 9th Edition 25-27; 1998.
2. Arjure D., Bodnar R.J. Inhibition of deprivation-induced feeding by naloxone and cholecystokinin in rats. Effects of central alloxan Brain Res. Bull. 24:1990;375-379.
3. Benedetti F. Cholecystokinin type A and type B receptors and their modulation of opioid analgesia. News Physiol. Sci. 12:1997;263-268.
4. Benedetti F., Amanzio M. The neurobiology of placebo analgesia from endogenous opioids to cholecystokinin. Prog. Neurobiol. 52:1998;109-125.
5. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain. 64:1996;535-543.
6. Benoliel J.J., Becker C., Mauborgne A., Bourgoin S., Hamon M., Cesselin F. Interactions between central opiodergic and cholecystokininergic systems in rate. Possible significance for the development of opioid tolerance Bull. Acad. Nat. Med. 182:1998;311-324.
7. Betancur C., Azzi M., Rostene W. Nonpeptide antagonists of neuropeptide receptors. Tools for research and therapy Trends Pharmacol. Sci. Rev. 18:1997;372-386.
8. Bock M.G., DePardo R.M., Evans B.E., Ritel K.E., Whitter W.L., Veber D.F., Anderson P.S., Freidinger R.M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands-L-365,260. J. Med. Chem. 32:1989;13-16.
9. Bridges R.S., Grimm C.T. Reversal of morphine disruption of maternal behavior by concurrent treatment with the opiate antagonist naloxone. Science. 218:1982;166-168.
10. Crawley J.N. Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12:1991;232-236.
11. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.F., Hawley D., Iverson S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176:1990;35-44.
12. Evans B.E., Bock M.G., Ritle K.E., DiPardo R.M., Whitter W.L., Veber D.F., Anderson P.S., Freidinger R.M. Design of potent orally effective non-peptide antagonists of the peptide hormone cholecystokinin. Proc. Natl. Acad. Sci. USA. 83:1986;4918-4922.
13. Faris P.L., Komisuruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219:1983;310-312.
14. Felicio L.F., Mann P.E., Bridges R.S. Intracerebroventricular cholecystokinin infusions block beta-endorphin-induced disruption of maternal behavior. Pharmacol. Biochem. Behav. 39:1991;201-204.
15. Freedman S.B., Patel S., Smith A.J., Chapman K., Fletcher A., Kemp J.A., Marshall G.R., Hargreaves R.J., Scholey K., Mellin E.C., DiPardo R.M., Bock M.G., Freidinger R.M. A second generation of non-peptide cholecystokinin receptor antagonists and their possible therapeutic potential. Ann NY Acad. Sci. 713:1994;312-318.
16. Grimm C.T., Bridges R.S. Opiate regulation of maternal behavior in the rat. Pharmacol. Biochem. Behav. 19:1983;609-616.
17. Itoh S., Katsuura G., Maeda Y. Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur. J. Pharmacol. 80:1982;421-425.
18. Kapas L., Benedek G., Penke B. Cholecystokinin interferes with the thermoregulatory effects of exogenous and endogenous opioids. Neuropeptides. 14:1989;85-92.
19. Kinsley C.H., Bridges R.S. Morphine treatment and reproductive condition alter olfactory preferences for pup and adult male odors in female rats. Dev. Psychobiol. 23:1990;331-347.
20. Kinsley C.H., Bridges R.S. Parity-associated reductions in behavioral sensitivity to opiates. Biol. Reprod. 39:1988;270-278.
21. Leng G., Dye S., Bicknell R.J. Kappa-opioid restraint of oxytocin secretion. plasticity through pregnancy Neuroendocrinology. 66:1997;378-383.
22. Linden A., Uvnas-Moberg K., Eneroth P., Sodersten P. Stimulation of maternal behavior in rats with cholecystokinin octapeptide. J. Neuroendocrinol. 1:1989;389-392.
23. Lucas G.A., Alster P., Brodin E., Wiesenfelf Z.H. Differential release of cholecystokinin by morphine in rat spinal cord. Neurosci. Lett. 245:1998;13-16.
24. Magnuson D.S.K., Sullivan A.F., Simonnet G., Roques B.P., Dickenson A.H. Differential interactions of cholecystokinin and FLFQPQRF-NH2 with mu and delta opioid antinociception in the rat spinal cord. Neuropeptides. 16:1990;213-218.
25. Mann P.E., Arjure D., Romero M.T., Pasternak G.W., Hahn E.F., Bodnar R.J. Differential sensitivity of opioid-induced feeding to naloxone and naloxonazine. Psychopharmacology (Berlin). 94:1988;336-341.
26. Mann P.E., Felicio L.F., Bridges R.S. Investigation into the role of cholecystokinin (CCK) in the induction and maintenance of maternal behavior in rats. Horm. Behav. 29:1995;392-406.
27. Mann P.E., Kinsley C.H., Bridges R.S. Opiate receptor subtype involvement in maternal behavior in lactating rats. Neuroendocrinology. 53:1991;487-492.
28. Mann P.E., Kinsley C.H., Ronsheim P.M., Bridges R.S. Long-term effects of parity on opioid and nonopioid behavioral and endocrine responses. Pharmacol. Biochem. Behav. 34:1989;83-88.
29. 1 opioid receptor involvement in maternal behavior. Physiol. Behav. 47:1990;133-138.
30. McKay L.D., Kenney N.J., Edens N.K., Williams R.H., Woods S.C. Intracerebroventricular beta-endorphin increases food intake in rats. Life Sci. 29:1981;1429-1434.
31. Melton P.M., Riley A.L. An assessment of the Interaction between cholecystokinin and the opiates within a drug discrimination procedure. Pharmacol. Biochem. Behav. 46:1993;237-242.
32. Millington W.R., Mueller G.P., Lavigne G.J. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary. J. Pharmacol. Exp. Ther. 261:1992;454-461.
33. Morley J.E., Levine A.S., Yim G.K., Lowy M.T. Opioid modulation of appetite. Neurosci. Biobehav. Rev. 7:1983;281-305.
34. Naruse G. Maternal behavior. Induction of biological regulation in the animal Encephale. 23:1997;380-384.
35. Nelson E.E., Panksepp J. Brain substrates of infant-mother attachment contribution of opioids, oxytocin and norepinephrine. Neurosci. Biobehav. 22:1998;437-452.
36. Panerai A.E., Rovati L.C., Cocco E., Sacerdote P., Mantegazza P. Dissociation of tolerance and dependence to morphine. A possible role for cholecystokinin Brain Res. 410:1987;52-60.
37. Rehfeld J.F. Immunochemical studies on cholecystokinin. J. Biol. Chem. 253:1978;4022-4030.
38. Riley A.L., Melton P.M. Effects of mu-and delta-opioid-receptor antagonists on the stimulus properties of cholecystokinin. Pharmacol. Biochem. Behavior. 57:1997;57-62.
39. Rubin B.S., Bridges R.S. Disruption of ongoing maternal responsiveness in rats by central administration of morphine sulfate. Brain Res. 307:1984;91-97.
40. Schafer M., Zhou L., Stein C. Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue. Neuroscience. 82:1998;603-611.
41. Skinner K., Basbaum A.I., Fields H.L. Cholecystokinin and enkephalin in brain stem pain modulating circuits. Neuroreport. 8:1997;2995-2998.
42. Smadja C., Maldonado R., Turcaud S., Founie-Zaluski M.C., Roques B.P. opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology (Berlin). 120:1995;400-408.
43. Stengaard-Pendersen K., Larsson L.I. Localization and opiate receptors binding of enkephalin, cholecystokinin, ACTH and β-endorphin in the rat central nervous system. Peptides. 2:1984;715-718.
44. Tieppo C.A., Ferreira F.S., Sassatani A.S., Felicio L.F., Nasello A.G. Stereotyped behavior induced by apomorphine (APO) and amphetamine are differently modulated by CCK antagonists. Naunyn Schiedebergs Arch. Pharmacol. 358(Suppl. 1):1998;R74.
45. Tieppo C.A., Nasello A.G., Felicio L.F. Modulation of apomorphine-induced stereotyped behavior by cholecystokinin. Prog. Neuropsychopharmacol. Biol. Psychiatry. 21:1997;683-695.
46. Tieppo C.A., Silva A.M.P., Palermo-Neto J., Nasello A.G., Felicio L.F. Intracerebroventricular cholecystokinin infusions reduce stereotypy in dopamine-supersensitive rats. Braz. J. Med. Biol. Res. 28:1995;351-354.
47. Vanderhaeghen J.J., Lotstra F., De Mey J., Gilles C. Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. Proc. Natl. Acad. Sci. USA. 77:1980;1190-1194.
48. Wank A.S., Pisegna R.J., Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann. NY Acad. Sci. 713:1994;49-66.
49. Wellman J., Carr D., Graham A., Jones H., Humm J.L., Ruscio M., Billack B., Kinsley C.H. Preoptic area infusions of morphine disrupt and naloxone restores parental like behavior in juvenile rats. Brain Res. Bull. 44:1997;183-191.
50. Wiesenfeld-Hallin Z., Xu J.X. The role of cholecystokinin in nociception neuropathic pain and opioid tolerance. Regul. Pept. 65:1996;23-28.
51. Wiesenfeld-Hallin Z., Xu J.X., Hughes J., Horwell D.C., Hokfelt T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. USA. 87:1990;7105-7109.
52. Xu X.J., Elfvin A., Hao J.X., Fournié Zaluski M.C., Roques B.P., Wiesenfeld Hallim Z. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level. Neuropeptides. 31:1997;287-291.
53. Zaias J., Okimoto L., Trivedi A., Mann P.E., Bridges R.S. Inhibitory effects of naltrexone on the induction of parental behavior in juvenile rat. Pharmacol. Biochem. Behav. 53:1996;987-993.
54. Zetler G. Antagonism of cholecystokinin-like peptides by opioid peptides, morphine or tetrodotoxin. Eur. J. Pharmacol. 60:1979;67-72.